Skip to main content

vildagliptin (Galvus®)

 

Following a limited submission

AWMSG advice

Status: Recommended

Vildagliptin (Galvus®) 50 mg tablets are recommended as an option for use within NHS Wales for the treatment of type 2 diabetes in patients with moderate or severe renal impairment.

 Final Recommendation: vildagliptin (Galvus) 1393 (PDF, 305Kb)
 Appraisal Report: vildagliptin (Galvus) 1393 (PDF, 237Kb)

Medicine details

Medicine name vildagliptin (Galvus®)
Formulation 50 mg tablet
Reference number 1393
Indication

Treatment of type 2 diabetes in patients with moderate or severe renal impairment

Company Novartis Pharmaceuticals UK Ltd
BNF chapter Endocrine system
Submission type Limited
Status Recommended
Advice number 3012
NMG meeting date 10/07/2012
AWMSG meeting date 12/09/2012
Ratification by Welsh Government 25/10/2012
Date of issue 25/10/2012
Date of last review November 2022
Further information

This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations

Follow AWTTC: